DM
Deerfield Management Portfolio holdings
AUM
$5.51B
This Quarter Return
-3.27%
1 Year Return
+12.76%
3 Year Return
+152.98%
5 Year Return
+204.91%
10 Year Return
+993.1%
AUM
$6.01B
AUM Growth
+$6.01B
(+4.6%)
Cap. Flow
+$36.4M
Cap. Flow
% of AUM
0.61%
Top 10 Holdings %
Top 10 Hldgs %
51.52%
Holding
592
New
224
Increased
125
Reduced
43
Closed
159
Top Buys
| 1 |
WAY
Waystar Holding Corp
WAY
|
$106M |
| 2 |
Gilead Sciences
GILD
|
$102M |
| 3 |
CVS Health
CVS
|
$57.6M |
| 4 |
Baxter International
BAX
|
$52.6M |
| 5 |
Cullinan Oncology
CGEM
|
$37.4M |
Top Sells
| 1 |
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
|
$136M |
| 2 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
$80.7M |
| 3 |
SWTX
SpringWorks Therapeutics
SWTX
|
$63.2M |
| 4 |
Oscar Health
OSCR
|
$38.2M |
| 5 |
Viking Therapeutics
VKTX
|
$38M |
Sector Composition
| 1 | Healthcare | 83.29% |
| 2 | Industrials | 0.67% |
| 3 | Technology | 0.57% |
| 4 | Financials | 0.44% |
| 5 | Consumer Discretionary | 0.33% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
BioNTech
BNTX
$24.1B
| $47.7M | 0.79% |
594,000
+24,426
| +4% | +$1.96M |
|
27
Disc Medicine
IRON
$2.14B
| $46.1M | 0.77% |
1,023,265
+357,730
| +54% | +$16.1M |
|
28
Enhabit
EHAB
$398M
| $44.6M | 0.74% |
4,997,746
| – | – |
|
29
CONMED
CNMD
$1.64B
| $43.8M | 0.73% |
631,264
+293,099
| +87% | +$20.3M |
|
30
Integra LifeSciences
IART
$1.18B
| $42.8M | 0.71% |
1,467,632
-5,458
| -0.4% | -$159K |
|
31
Bio-Rad Laboratories Class A
BIO
$7.8B
| $41.4M | 0.69% |
151,714
-664
| -0.4% | -$181K |
|
32
Day One Biopharmaceuticals
DAWN
$766M
| $40.3M | 0.67% |
2,923,137
+1,157,825
| +66% | +$16M |
|
33
Galapagos
GLPG
$2.06B
| $35M | 0.58% |
1,411,000
| – | – |
|
34
Embecta
EMBC
$837M
| $34.1M | 0.57% |
2,726,135
| – | – |
|
35
Structure Therapeutics
GPCR
$1.14B
| $33.2M | 0.55% |
844,407
-189,273
| -18% | -$7.43M |
|
36
Cogent Biosciences
COGT
$1.83B
| $31.6M | 0.53% |
3,744,263
+2,209,918
| +144% | +$18.6M |
|
37
Alnylam Pharmaceuticals
ALNY
$58.6B
| $29.1M | 0.48% |
+119,800
| New | +$29.1M |
|
38
Perspective Therapeutics
CATX
$251M
| $28.1M | 0.47% |
2,817,763
-25,359,873
| -90% | -$10 |
|
39
Pharvaris
PHVS
$1.41B
| $26.3M | 0.44% |
1,397,279
+335,687
| +32% | +$6.31M |
|
|
MREO
40
Mereo BioPharma
MREO
$275M
| $24.2M | 0.4% |
+6,710,429
| New | +$24.2M |
|
41
Insulet
PODD
$24.2B
| $22.7M | 0.38% |
112,433
+2,372
| +2% | +$479K |
|
42
Nkarta
NKTX
$149M
| $22.5M | 0.37% |
3,799,143
-1,394,944
| -27% | -$8.24M |
|
43
DocGo
DCGO
$152M
| $22.2M | 0.37% |
7,195,956
+2,091,569
| +41% | +$6.46M |
|
44
InMode
INMD
$917M
| $21.3M | 0.35% |
1,166,704
| – | – |
|
45
PACS Group
PACS
$1.71B
| $19.6M | 0.33% |
+663,851
| New | +$19.6M |
|
46
Lantheus
LNTH
$3.75B
| $19.3M | 0.32% |
240,218
+31
| +0% | +$2.49K |
|
47
Castle Biosciences
CSTL
$673M
| $19M | 0.32% |
874,609
-53,408
| -6% | -$1.16M |
|
48
NewAmsterdam Pharma
NAMS
$2.8B
| $16.7M | 0.28% |
869,250
+202,250
| +30% | +$3.89M |
|
49
Prelude Therapeutics
PRLD
$69.1M
| $15.7M | 0.26% |
4,133,000
| – | – |
|
50
Kyverna Therapeutics
KYTX
$161M
| $14.9M | 0.25% |
1,983,000
+520,663
| +36% | +$3.9M |
|